Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2533-2542

  Mayordomo, José Ignacio ^a,j   López, Andrés ^b   Viñolas, Núria ^c   Castellanos, Javier ^d   Pernas, Sonia ^e   Alonso, Juan Domingo ^f   Frau, Adolfo ^g   Layola, Miquel ^h   Gasquet, José Antonio ⁱ   Sánchez, Jordi ⁱ  

^a Lozano Blesa Hospital   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c H Clinic i Provincial   (Spain)

^d Department of Pneumology   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^g HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^h IQVIA   (United States)

ⁱ Amgen SA   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

more..

Author keywords

Drug therapy; Fever; Healthcare costs; Neutropenia

Indexed keywords

AMINOGLYCOSIDE; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CEPHALOSPORIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; PREDNISOLONE; QUINOLONE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SPAIN; THERAPY DELAY; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; FEMALE; FEVER; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; SPAIN;

EID: 70349311596     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903209563     Document Type: Article

References (34)

1. Gandhi SK, Arguelles L, Boyer G. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 2001;21:684-690 (Pubitemid 32506484)
2. Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 1996;3:519-523 (Pubitemid 27062011)
3. Siena S, Piccart M, Holmes F, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10:715-724
4. Lyman G, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-1864 (Pubitemid 28535432)
5. Westermann AM, Taal BG, Swart M, et al. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. Pharmacol Res 2000;42:151-156 (Pubitemid 30658943)
6. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-2076
7. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-2409
8. Smith T, Khatcheressian J, Lyman G, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205 (Pubitemid 46638957)
9. Klastersky J. Febrile neutropenia. Curr Opin Oncol 1993;5:625-632
10. Johnston E, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 1998;25:552-561 (Pubitemid 28478061)
11. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311 (Pubitemid 29350300)
12. Uyl-de Groot CA, Vellenga E, De Vries EG, et al. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomized placebo-controlled trial. Pharmacoeconomics 1997;12:351-360
13. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-1924 (Pubitemid 40563265)
14. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266 (Pubitemid 43673249)
15. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl. 1):1-15
16. Green M, Koelbl H, Baselga J, et al. A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35 (Pubitemid 36150255)
17. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731 (Pubitemid 34111380)
18. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184
19. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy- induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-2453 (Pubitemid 44442936)
20. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-3167 (Pubitemid 47218066)
21. García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-38 (Pubitemid 32060887)
22. Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803-808
23. Freifeld AG, Walsh TJ, Pizzo PA. Infection in the cancer patient. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice in Oncology. Philadelphia, USA: Lippincott-Raven, 1997: pp. 2659-2699
24. Grever HR, Chabner B. Cancer drug discovery and development. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice in Oncology. Philadelphia, USA: Lippincott-Raven, 1997: pp. 385-394
25. Gisbert R, Brosa M. [CD-ROM database] Base de datos de Costes Sanitarios. SOIKOS Versión 2.2. Barcelona: Centre d'Estudis en Economía de la Salut i de la Política Social, 2005
26. Consejo General de Colegios Oficiales de Farmacéuticos. [CD-ROM database]. BOT Plus: base de datos del conocimiento sanitario, 7th update (01/09/2005). Madrid: CGCOF, 2006
27. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30:S51-9 (Pubitemid 47505301)
28. Timmer-Bonte JNH, Adang EMM, Smit JHM, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 2006;24:2991-2997
29. Cosler LE, Eldar-Lissai A, Culakova E, et al. Therapeutic use of granulocyte colony-stimulating factor for established febrile neutropenia. Effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343-351
30. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129-146
31. Bennet CL, Calhoun EA. Evaluating the total cost of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-483
32. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implication for quality and cost of care. J Clin Oncol 2000;18:3699-3706 (Pubitemid 30816228)
33. Leese B. The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 1993;29(Suppl. 7):S15-S18
34. Leonard RC, Miles D, Thomas R, et al. UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-2068